• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sarah Faulkner

Teva inks deal to test drugs with ProBioGen’s artificial lymph node tech

February 7, 2018 By Sarah Faulkner

ProBiogen

Teva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates. ProBioGen, a contract developer and manufacturer based in Berlin, designed its 3D micro-organoid model for companies to use to predict the reactions that their drugs will provoke in the […]

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: probiogen, Teva Pharmaceuticals

Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients

February 6, 2018 By Sarah Faulkner

asthma inhaler

Researchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures. Previous research has shown that the inhaled drugs, used to treat COPD, impact bone mineral density based on the dose of the corticosteroid, especially in post-menopausal […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Research & Development Tagged With: Novartis

Machine-learning model helps detect diabetic patients at risk for kidney damage

February 6, 2018 By Sarah Faulkner

Medial EarlySign

Medial EarlySign touted data today from a study of its algorithm designed to identify diabetic patients who have the highest risk of developing renal dysfunction. The company’s machine-learning model looks at data from electronic health records to make predictions about patients’ health. In this study, the company reported that the algorithm identified 45% of patients who […]

Filed Under: Diabetes, Diagnostics, Featured, Hospital Care, Technology Tagged With: medialearlysign

BTG touts one-year follow-up data for Ekos pulmonary embolism therapy

February 6, 2018 By Sarah Faulkner

Ekos

BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: BTG

Portal Instruments uses speed to tackle needle-free drug delivery

February 6, 2018 By Sarah Faulkner

Portal Instruments

Nobody likes to be on the receiving end of a shot. Studies have found that needle anxiety keeps people from getting important medications, like the flu vaccine, and can even stop people from taking self-injected drugs to manage chronic illnesses. That’s a problem that Portal Instruments hopes to solve with its needle-free injection system. “By […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: portal instruments

Amiko wins CE Mark to integrate drug sensor tech into inhalers

February 5, 2018 By Sarah Faulkner

Amiko

Amiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals‘ (NYSE:TEVA) Spiromax inhaler, Chiesi‘s Nexthaler device and GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler. The company’s Respiro platform is designed to help doctors monitor, in real-time, when and how well patients are using their medications. “Respiro’s medication […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: amiko, chiesigroup, GlaxoSmithKline plc, Teva Pharmaceuticals

Novo Nordisk launches two new diabetes drugs in U.S.

February 5, 2018 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S. The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December. Fiasp, a fast-acting mealtime insulin, is indicated for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

Cam Med partners with JDRF to develop flexible, bandage-like insulin patch pump

February 5, 2018 By Sarah Faulkner

JDRF

Medical device startup Cam Med has partnered with JDRF to develop an ultra-thin, flexible insulin patch pump to be used with next-generation artificial pancreas systems. The goal of the partnership is to speed up the development of Cam Med’s Evopump – a conformable, disposable patch pump – so that the device can be integrated into […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: cammed, Juvenile Diabetes Research Foundation (JDRF)

Intarcia slashes headcount after FDA rejects diabetes drug-device combo

February 5, 2018 By Sarah Faulkner

Intarcia Therapeutics

Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants Tagged With: Intarcia Therapeutics

Delcath touts 500th commercial Chemosat treatment in Europe

February 2, 2018 By Sarah Faulkner

Delcath Systems

Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system. The drug-device combo has been available in certain European markets since 2012. “This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 74
  • Page 75
  • Page 76
  • Page 77
  • Page 78
  • Interim pages omitted …
  • Page 241
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS